Biotech · Public company · Rockville, MD, US

Macrogenics Inc

Ticker MGNX · SEC CIK 0001125345

Track this companyFree. Adds Macrogenics Inc to your Dealase workspace and tells you when its record changes.

Clinical trials2512 recruiting or active

Pipeline programs38From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline38

ChemotherapyPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
margetuximabPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
MargetuximabPhase 3 · HER-2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Physician's choice of chemotherapy.Phase 3 · HER-2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
RetifanlimabPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
TebotelimabPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
TrastuzumabPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
TrastuzumabPhase 3 · HER-2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
AbirateronePhase 2 · Castration-Resistant Prostatic CancerClinicalTrials.gov · fetched Nov 12, 2026
docetaxelPhase 2 · Androgen-Independent Prostatic CancerClinicalTrials.gov · fetched Nov 12, 2026
EnzalutamidePhase 2 · Castration-Resistant Prostatic CancerClinicalTrials.gov · fetched Nov 12, 2026
lorigerlimabPhase 2 · Androgen-Independent Prostatic CancerClinicalTrials.gov · fetched Nov 12, 2026
LorigerlimabPhase 2 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
MargetuximabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Margetuximab 10 mg/kgPhase 2 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
Margetuximab 15 mgPhase 2 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 2 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
PrednisonePhase 2 · Androgen-Independent Prostatic CancerClinicalTrials.gov · fetched Nov 12, 2026
vobramitamab duocarmazinePhase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
vobramitamab duocarmazinePhase 2 · Castration-Resistant Prostatic CancerClinicalTrials.gov · fetched Nov 12, 2026
vobramitamab duocarmazine 2.0 mg (Arm A)Phase 2 · Castration-Resistant Prostatic CancerClinicalTrials.gov · fetched Nov 12, 2026
vobramitamab duocarmazine 2.7 mg (Arm B)Phase 2 · Castration-Resistant Prostatic CancerClinicalTrials.gov · fetched Nov 12, 2026
Enoblituzumab Schedule 1Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Enoblituzumab Schedule 2Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
lorigerlimabPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
LorigerlimabPhase 1 · Squamous Cell Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
MGC026 Dose EscalationPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
MGC026 Dose for ExpansionPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
MGC028Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
MGC030Phase 1 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
MGD014Phase 1 · Human Immunodeficiency Virus I InfectionClinicalTrials.gov · fetched Nov 12, 2026
MGD020Phase 1 · Human Immunodeficiency Virus I InfectionClinicalTrials.gov · fetched Nov 12, 2026
MGD024Phase 1 · Leukemia, Acute MyeloidClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
PembrollizumabPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
retifanlimabPhase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
vobramitamab duocarmazinePhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
vobramitamab tavatecanPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination DeficiencyPHASE2 · RECRUITING · started Jan 1, 2027ClinicalTrials.gov NCT07565155 · fetched Nov 12, 2026
A Study of MGC030 in Participants With Advanced Solid TumorsPHASE1 · RECRUITING · started Oct 7, 2026ClinicalTrials.gov NCT07822399 · fetched Nov 12, 2026
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]PHASE2 · RECRUITING · started Feb 11, 2026ClinicalTrials.gov NCT07071961 · fetched Nov 12, 2026
A Study of Lorigerlimab in Participants With Advanced Solid TumorsPHASE2 · RECRUITING · started May 1, 2025ClinicalTrials.gov NCT06730347 · fetched Nov 12, 2026
A Study of MGC028 in Participants With Advanced Solid TumorsPHASE1 · RECRUITING · started Feb 13, 2025ClinicalTrials.gov NCT06723236 · fetched Nov 12, 2026
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 15, 2024ClinicalTrials.gov NCT06227546 · fetched Nov 12, 2026
A Study of MGC026 in Participants With Advanced Solid TumorsPHASE1 · RECRUITING · started Mar 6, 2024ClinicalTrials.gov NCT06242470 · fetched Nov 12, 2026
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 16, 2024ClinicalTrials.gov NCT06014255 · fetched Nov 12, 2026
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerPHASE2 · COMPLETED · started Sep 28, 2023ClinicalTrials.gov NCT05848011 · fetched Nov 12, 2026
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsPHASE2 · TERMINATED · started Jun 13, 2023ClinicalTrials.gov NCT05551117 · fetched Nov 12, 2026
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)PHASE2 · RECRUITING · started Dec 13, 2022ClinicalTrials.gov NCT05475171 · fetched Nov 12, 2026
Post-transplant Flotetuzumab for AMLPHASE1 · COMPLETED · started Oct 20, 2022ClinicalTrials.gov NCT05506956 · fetched Nov 12, 2026
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral TherapyPHASE1 · COMPLETED · started Sep 26, 2022ClinicalTrials.gov NCT05261191 · fetched Nov 12, 2026
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 13, 2022ClinicalTrials.gov NCT05362773 · fetched Nov 12, 2026
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsPHASE1 · COMPLETED · started Apr 19, 2022ClinicalTrials.gov NCT05293496 · fetched Nov 12, 2026
MARGetuximab Or Trastuzumab (MARGOT)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 13, 2020ClinicalTrials.gov NCT04425018 · fetched Nov 12, 2026
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerPHASE2_PHASE3 · COMPLETED · started Sep 30, 2019ClinicalTrials.gov NCT04082364 · fetched Nov 12, 2026
MGD019 DART® Protein in Unresectable/Metastatic CancerPHASE1 · COMPLETED · started Dec 12, 2018ClinicalTrials.gov NCT03761017 · fetched Nov 12, 2026
MGC018 With or Without MGA012 in Advanced Solid TumorsPHASE1_PHASE2 · TERMINATED · started Nov 21, 2018ClinicalTrials.gov NCT03729596 · fetched Nov 12, 2026
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 14, 2017ClinicalTrials.gov NCT02923180 · fetched Nov 12, 2026
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerPHASE1_PHASE2 · COMPLETED · started Jan 1, 2016ClinicalTrials.gov NCT02689284 · fetched Nov 12, 2026
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerPHASE3 · COMPLETED · started Aug 24, 2015ClinicalTrials.gov NCT02492711 · fetched Nov 12, 2026
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerPHASE1 · COMPLETED · started Jul 1, 2015ClinicalTrials.gov NCT02475213 · fetched Nov 12, 2026
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerPHASE2 · COMPLETED · started Mar 1, 2013ClinicalTrials.gov NCT01828021 · fetched Nov 12, 2026
Safety Study of MGAH22 in HER2-positive CarcinomasPHASE1 · COMPLETED · started Jul 1, 2010ClinicalTrials.gov NCT01148849 · fetched Nov 12, 2026

SEC filings12

8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 23, 2026 · fetched Nov 12, 2026
8-K/A · 8-K/ASEC EDGAR · filed Sep 3, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 23, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 8, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 7, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 20, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026